Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BPTH

Bio-Path Holdings Inc

Dec 11 • 04:00PM ET

0.7150

Dollar change -0.0250
Percentage change -3.38	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA PFE BNTX ARWR ALNY IONS BCRX VIR GERN ONCY

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.20	Insider Own	0.05%	Shs Outstand	4.31M	Perf Week	5.63%
Market Cap	3.08M	Forward P/E	-	EPS next Y	-1.55	Insider Trans	0.00%	Shs Float	4.30M	Perf Month	-20.47%
Income	-10.51M	PEG	-	EPS next Q	-0.37	Inst Own	1.37%	Short Float	0.72%	Perf Quarter	-26.80%
Sales	0.00M	P/S	-	EPS this Y	90.57%	Inst Trans	-58.10%	Short Ratio	0.03	Perf Half Y	-66.43%
Book/sh	-0.19	P/B	-	EPS next Y	51.10%	ROA	-263.29%	Short Interest	0.03M	Perf Year	-92.89%
Cash/sh	0.13	P/C	5.50	EPS next 5Y	-	ROE	-1159.74%	52W Range	0.59 - 12.00	Perf YTD	-92.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	34.89%	ROI	-	52W High	-94.04%	Beta	0.21
Dividend TTM	-	Quick Ratio	0.86	Sales past 5Y	0.00%	Gross Margin	-	52W Low	20.52%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	0.86	EPS Y/Y TTM	70.49%	Oper. Margin	-	RSI (14)	41.60	Volatility	24.26% 14.73%
Employees	10	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	12.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	88.99%	Payout	-	Rel Volume	0.60	Prev Close	0.74
Sales Surprise	-	EPS Surprise	31.37%	Sales Q/Q	-	Earnings	Nov 15 BMO	Avg Volume	1.17M	Price	0.71
SMA20	-5.65%	SMA50	-21.69%	SMA200	-66.04%	Trades		Volume	701,415	Change	-3.38%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-21	Initiated	ROTH Capital	Buy	$13
Nov-13-17	Reiterated	H.C. Wainwright	Buy	$4.50 → $1.50
Aug-10-16	Reiterated	Maxim Group	Buy	$5 → $2
Apr-18-16	Initiated	Rodman & Renshaw	Buy	$5
Jun-02-14	Resumed	Maxim Group	Buy	$5
May-09-14	Initiated	Maxim Group	Buy	$5

Today 07:00AM	Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients (GlobeNewswire)
Nov-20-24 08:00PM	Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
Nov-15-24 07:19AM	Bio-Path: Q3 Earnings Snapshot (Associated Press Finance) -9.72%
07:00AM	Bio-Path Holdings Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-08-24 07:00AM	Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024 (GlobeNewswire)
05:24PM	Loading…
Oct-10-24 05:24PM	Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-09-24 06:27PM	Bio-Path Holdings Inc (BPTH) Q2 2024 Earnings Call Highlights: Financial Improvements and ... (GuruFocus.com) -7.56%
Oct-08-24 08:00PM	Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +39.79%
09:51AM	ACHR, BPTH, PLUG, REGRF: (News Direct)
09:27AM	Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer (Benzinga)
07:00AM	Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity (GlobeNewswire)
Sep-16-24 07:00AM	Bio-Path Holdings Announces Publication in Biomedicines (GlobeNewswire)
Sep-04-24 05:48PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24 (Newsfile) -5.70%
Sep-03-24 07:00AM	Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-21-24 07:00AM	Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors (GlobeNewswire)
07:15AM	Loading…
Aug-15-24 07:15AM	Bio-Path: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Bio-Path Holdings Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-08-24 07:00AM	Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 (GlobeNewswire)
Jul-08-24 07:00AM	Bio-Path Holdings Provides Clinical Update and Expansion Plans (GlobeNewswire)
Jun-18-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -5.02%
Jun-17-24 09:45AM	Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase (GlobeNewswire) +10.65%
Jun-14-24 07:00AM	Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress (GlobeNewswire) +8.00%
Jun-05-24 05:46PM	Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -12.58%
Jun-04-24 04:55PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24 (Newsfile)
08:00AM	Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jun-03-24 07:00AM	Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +56.80%
May-24-24 07:00AM	Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress (GlobeNewswire)
May-23-24 05:00PM	Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -5.19%
May-16-24 03:02AM	Bio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ... (GuruFocus.com)
12:12AM	Q1 2024 Bio Path Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
10:53AM	Loading…
May-15-24 10:53AM	BPTH Stock Earnings: Bio-Path Holdings Misses EPS for Q1 2024 (InvestorPlace) -13.18%
07:19AM	Bio-Path: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Bio-Path Holdings Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-08-24 07:00AM	Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 (GlobeNewswire) -8.00%
Apr-19-24 12:14PM	Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
10:14AM	Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study (Zacks)
Apr-18-24 01:57PM	Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +29.63%
07:00AM	Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients (GlobeNewswire)
Apr-15-24 07:00AM	Bio-Path Holdings Expands Global Patent Portfolio (GlobeNewswire)
Apr-02-24 07:00AM	Bio-Path Holdings Provides 2024 Clinical and Operational Update (GlobeNewswire) -7.93%
Mar-27-24 04:43PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23 (Newsfile)
Mar-10-24 08:17AM	Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-08-24 10:45PM	Q4 2023 Bio Path Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -6.42% -9.95%
07:00AM	Bio-Path Holdings Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 07:00AM	Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024 (GlobeNewswire)
Feb-21-24 07:00AM	Bio-Path Holdings Announces 1-for-20 Reverse Stock Split (GlobeNewswire)
Jan-10-24 07:00AM	Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients (GlobeNewswire) +5.64%
Dec-14-23 07:00AM	Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (GlobeNewswire)
Nov-20-23 12:54PM	Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-15-23 07:12AM	Bio-Path: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Bio-Path Holdings Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-08-23 07:00AM	Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023 (GlobeNewswire) -7.78%
Oct-24-23 07:00AM	Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia (GlobeNewswire) +10.36%
Sep-08-23 04:01PM	Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -5.10%
Aug-30-23 05:11PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23 (Newsfile) +7.50%
Aug-15-23 10:04PM	Q2 2023 Bio Path Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -11.66% +7.92%
07:06AM	Bio-Path: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Bio-Path Holdings Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-08-23 07:00AM	Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023 (GlobeNewswire) +24.36%
Aug-03-23 08:22AM	Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering (GlobeNewswire) -46.02%
Aug-01-23 07:00AM	Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (GlobeNewswire) -7.54%
Jul-17-23 07:00AM	Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors (GlobeNewswire)
Jun-02-23 04:49PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23 (Newsfile) -5.83%
May-18-23 12:41PM	Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 09:13PM	Q1 2023 Bio Path Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
07:06AM	Bio-Path: Q1 Earnings Snapshot (AP Finance)
07:00AM	Bio-Path Holdings Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-05-23 07:00AM	Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023 (GlobeNewswire) +8.63%
Apr-10-23 05:25PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 '22 (Newsfile)
Apr-04-23 01:19PM	Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-03-23 08:37AM	Market Sentiment Around Loss-Making Bio-Path Holdings, Inc. (NASDAQ:BPTH) (Simply Wall St.)
Mar-31-23 07:00AM	Bio-Path Holdings Reports Full Year 2022 Financial Results (GlobeNewswire) -18.71%
Mar-24-23 04:01PM	Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023 (GlobeNewswire)
Mar-16-23 07:00AM	Bio-Path Holdings Provides Clinical and Operational Update (GlobeNewswire)
Dec-28-22 09:59AM	Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-07-22 07:00AM	Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors (GlobeNewswire) -5.88%
Nov-15-22 07:00AM	Bio-Path Holdings Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-08-22 07:00AM	Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022 (GlobeNewswire) -7.80%
Nov-07-22 07:00AM	Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -45.96%
Oct-24-22 07:00AM	Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients (GlobeNewswire)
Oct-23-22 09:36AM	We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-30-22 11:24AM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) (Newsfile)
Sep-06-22 07:00AM	Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-16-22 07:00AM	Bio-Path Holdings Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-09-22 07:00AM	Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022 (GlobeNewswire)
Jun-13-22 12:10PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (Nasdaq:BPTH) (ACCESSWIRE)
May-17-22 07:00AM	Bio-Path Holdings Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-16-22 07:51AM	We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-10-22 07:00AM	Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022 (GlobeNewswire)
Apr-13-22 04:30PM	Stonegate Capital Partners Updates Coverage On Bio-Path Holdings, Inc. (NASDAQ:BPTH) (ACCESSWIRE) -17.02%
Apr-12-22 04:01PM	Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Apr-06-22 07:00AM	Bio-Path Holdings Appoints Aline Sherwood to Board of Directors (GlobeNewswire)
Mar-11-22 07:00AM	Bio-Path Holdings Reports Full Year 2021 Financial Results (GlobeNewswire) -8.07%
Mar-08-22 04:30PM	Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting (GlobeNewswire) +7.69%
Mar-04-22 07:00AM	Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022 (GlobeNewswire)
Jan-05-22 07:00AM	Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference (GlobeNewswire)
Dec-13-21 07:00AM	Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting (GlobeNewswire) -7.94%
Dec-06-21 04:22AM	Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation (Simply Wall St.)
Nov-12-21 07:00AM	Bio-Path Holdings Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Nov-05-21 08:00AM	Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021 (GlobeNewswire)

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BPTH

Bio-Path Holdings Inc

Upgrade your FINVIZ experience